Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

19
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
19
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

18
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
18
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

3.6K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS.

Biomedicines·2025
Same author

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2025
Same author

Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis.

Muscle & nerve·2025
Same author

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

JAMA neurology·2025

Related Experiment Video

Updated: Aug 16, 2025

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.3K

Inclusion Body Myositis.

Namita A Goyal

    Continuum (Minneapolis, Minn.)
    |December 20, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Inclusion body myositis (IBM), a frequently misdiagnosed muscle disorder, is now more easily diagnosed through advanced pathology and biomarkers. Recent research into IBM's mechanisms informs new therapeutic strategies.

    More Related Videos

    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
    09:17

    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

    Published on: August 24, 2017

    7.8K
    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    8.9K

    Related Experiment Videos

    Last Updated: Aug 16, 2025

    Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
    09:01

    Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

    Published on: June 5, 2010

    14.3K
    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
    09:17

    Minimally Invasive Muscle Embedding MIME - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis

    Published on: August 24, 2017

    7.8K
    Immunolabelling Myofiber Degeneration in Muscle Biopsies
    06:37

    Immunolabelling Myofiber Degeneration in Muscle Biopsies

    Published on: December 5, 2019

    8.9K

    Area of Science:

    • Neurology
    • Immunology
    • Pathology

    Background:

    • Inclusion body myositis (IBM) is a challenging myopathy subtype often misdiagnosed due to insidious onset and slow progression, particularly in older adults.
    • Historically, IBM pathogenesis was poorly understood, complicating early and accurate diagnosis.

    Approach:

    • Utilizing specialized muscle pathology stains to identify characteristic features.
    • Employing diagnostic tools like the anti-cytosolic 5'-nucleotidase 1A antibody biomarker.
    • Leveraging muscle imaging to detect specific patterns of muscle involvement.

    Key Points:

    • Advancements in diagnostic techniques, including pathology, biomarkers, and imaging, facilitate earlier recognition of IBM.
    • Emerging research suggests autophagy and cytotoxic T cell mechanisms are central to IBM pathogenesis.
    • Improved understanding of IBM is driving enhanced disease management and novel therapeutic development.

    Conclusions:

    • Earlier and more accurate diagnosis of IBM is now achievable through integrated clinical and diagnostic advancements.
    • Ongoing research into IBM's underlying mechanisms is paving the way for effective therapeutic interventions.
    • Current and future drug trials for IBM are built upon a foundation of improved disease understanding and management strategies.